Sermorelin vs ipamorelin
Sermorelin vs ipamorelin: differences, evidence and safety
Sermorelin vs ipamorelin is a comparison between two ways of stimulating growth-hormone release. Sermorelin acts through the GHRH receptor; ipamorelin acts through the ghrelin receptor. The human evidence reviewed here does not establish which is better for fat loss, muscle growth, recovery or anti-aging. FDA has identified specific safety and product-quality concerns with compounded ipamorelin, while current compounded sermorelin products are also not FDA-approved. A different receptor or a larger hormone response is not proof of a better health outcome.
Selected human studies and FDA sources, not a systematic review. Evidence for an IV drug after surgery does not validate a subcutaneous wellness injection or a peptide combination.
| Question | Sermorelin | Ipamorelin |
|---|---|---|
| Which receptor pathway? | Growth hormone-releasing hormone (GHRH) receptor. | Ghrelin receptor; a different growth-hormone secretagogue pathway. |
| Current FDA-approved longevity product? | No. The online compounded products reviewed here are not FDA-approved. | No FDA-approved longevity product established by these sources. |
| What human research is compared? | A small historical GHRH(1-29) study in older men. | A randomized IV trial after bowel surgery, not a wellness or muscle-building trial. |
| Which has better clinical outcomes? | No head-to-head winner established here. | No head-to-head winner established here. |
| What quality or safety question matters? | Exact compounded product, clinical suitability and pharmacy quality. | FDA flags immunogenicity, impurities and insufficient safety information for certain injection routes. |
What human evidence supports sermorelin and ipamorelin?
Swipe the study table sideways to read all four columns.
| Study and route | People and duration | Finding | What it does not show |
|---|---|---|---|
| Vittone et al., 1997: subcutaneous GHRH(1-29) | 11 older men with low baseline IGF-I; six weeks | Nighttime GH increased; some strength tests improved, without a change in measured muscle or fat mass. | Superiority over ipamorelin, long-term safety or results for every current sermorelin formulation. |
| Beck et al., 2014: IV ipamorelin versus placebo | 117 enrolled after bowel surgery; 114 in safety/modified intention-to-treat analysis; up to seven days or discharge | Time to first tolerated meal was 25.3 versus 32.6 hours; the difference was not statistically significant (p=0.15). | Benefit for muscle, fat loss, sleep or recovery from exercise; safety of home subcutaneous use. |
What is the main difference between sermorelin and ipamorelin?
Sermorelin is a GHRH analogue; ipamorelin is a ghrelin-receptor agonist. Both can stimulate growth-hormone release through different receptor pathways. Neither is the same as directly administering recombinant growth hormone.
Receptor biology explains how a substance acts. It cannot by itself establish which treatment improves a person's sleep, strength or body composition.
Which is better for fat loss, muscle growth or recovery?
The selected human studies do not establish a winner. The GHRH study above had only 11 men and found no change in measured muscle or fat mass. The ipamorelin trial evaluated return of bowel function after surgery, a different clinical question.
A claim about faster workout recovery cannot be supported by relabeling postoperative bowel recovery. To compare the two products fairly, look for a direct human trial measuring your intended outcome with the actual formulations and routes.
Is ipamorelin FDA-approved or permitted for compounding?
The FDA materials reviewed here do not identify an approved ipamorelin product. FDA's current risk page lists ipamorelin acetate in 503B Category 2, indicating significant safety concerns. Its 2024 evaluation also weighed against adding ipamorelin-related substances to the 503A Bulks List.
These are distinct regulatory records, not a blanket explanation of every pharmacy's legal position. A clinic's willingness to sell a product does not establish FDA approval. Today's compounded sermorelin is not FDA-approved either; historical Geref status does not transfer to it.
Is ipamorelin safer than sermorelin?
The sources do not establish a comparative safety advantage. FDA flags possible immune reactions from peptide aggregation and impurities, and insufficient information about the safety of certain ipamorelin injection routes.
FDA's review noted serious events, including deaths, in the IV postoperative study; whether the deaths were related to ipamorelin was unclear. Those findings neither prove causation nor establish safety for a different route. Compounded sermorelin also requires attention to product quality and individual clinical assessment.
Can sermorelin and ipamorelin be combined?
A proposed combination is a separate treatment claim. Different receptor pathways do not demonstrate that the combination improves outcomes or is safe. The studies in this comparison did not test the combination for anti-aging or exercise recovery.
Do not combine, substitute or convert doses using this comparison. Ask the prescriber for human evidence on the exact combination, why it is being proposed and how benefit and adverse effects would be monitored.
What should I compare in an online peptide plan?
Check the ingredient, route, quantity, first charge, renewal, laboratory costs, dispensing pharmacy and cancellation terms. Ask whether any supporting study actually used that product and route.
Our provider comparison covers documented sermorelin offers, not an equivalent ipamorelin market audit. Listing sermorelin plans here is not a finding that sermorelin is clinically superior.
Which sources support this comparison?
These sources were checked October 10, 2026. They define the product, population and regulatory boundaries used above; they do not determine individual suitability.
- FDA: bulk substances that may present significant compounding risks
- FDA: ipamorelin evaluation presented to PCAC (October 2024)
- FDA: understanding the risks of compounded drugs
- Vittone et al.: six-week GHRH(1-29) study in older men (1997)
- Beck et al.: randomized IV ipamorelin postoperative trial (2014)
- FDA: discontinued Geref sermorelin determination (2013)
Popular X vs Y questions
Continue with another evidence comparison.
We publish a comparison when people are searching for the distinction, even when only one side has audited providers. Inclusion is not an endorsement.
Sermorelin vs HGH
Compare current compounded sermorelin offers with prescription somatropin by product, FDA status, adult growth hormone deficiency evidence and what a plan price includes.
Sermorelin vs tesamorelin
Compare sermorelin vs tesamorelin for fat loss and muscle claims, human study results, FDA status and safety. Understand EGRIFTA WR and compounded products.
Sermorelin vs CJC-1295
Compare sermorelin and CJC-1295 by product identity, duration claims, FDA status and evidence limits. Understand why CJC-1295 forms cannot be grouped together.
These are products marketed in the longevity category, not established lifespan-extension treatments. Compounded drugs are not FDA-approved. This publication compares public information; a clinician must assess individual suitability. How we compare.